

**Amendments to the Claims:**

1. **(Currently Amended)** A method for treating a neurodegenerative illness of the central nervous system in a patient comprising culturing neuronal cells *in vitro* with an effective amount of at least one immunosuppressive compound having an affinity for immunophilins selected from the group consisting of FK506, cyclosporin A and rapamycin; and transplanting said cultured neuronal cells into said patient, said neurodegenerative illness of the central nervous system selected from the group consisting of Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease and ischemic cerebral stroke, and said effective amount for said cell culturing being that amount which will promote growth, survival and integration of said neuronal cells.

2. **(Currently Amended)** The method of Claim 1, further comprising administering to said patient an effective amount of said at least one immunosuppressive compound having an affinity for immunophilins during transplantation of said neuronal cells, said effective amount for said patient being that amount which will promote growth, survival and integration of said neuronal cells.

3. **(Withdrawn)**

4. **(Original)** The method of Claim 1, wherein said neuronal cells are second trimester human fetal neuronal cells.

5. **(Cancelled)**

6. **(Cancelled)**

7 - 13 **(Withdrawn)**

14. **(Currently Amended)** A method for treating a neurodegenerative illness of the central nervous system in a patient comprising transplanting neuronal cells, which have been cultured with an effective amount of at least one immunosuppressive compound having an affinity for immunophilins selected from the group consisting of FK506, cyclosporin A and rapamycin into said patient, said neurodegenerative illness selected from the group consisting of Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease and ischemic cerebral stroke, and said effective amount for said cell culturing being that amount which will promote growth, survival and integration of said neuronal cells.

15. **(Currently Amended)** The method of Claim 14, further

comprising administering to said patient an effective amount of said at least one immunosuppressive compound having an affinity for immunophilins during transplantation of said neuronal cells,

said effective amount for said patient being that amount which will promote growth, survival and integration of said neuronal cells.

**16. (Withdrawn)**

**17. (Original)** The method of Claim 14, wherein said neuronal cells are second trimester human fetal neuronal cells.

**18 – 28 (Withdrawn)**

**29. (Previously Presented)** The method of Claim 1, wherein said compound having an affinity for immunophilins is FK506.

**30. (Previously Presented)** The method of Claim 1, wherein said compound having an affinity for immunophilins is rapamycin.

**31. (Previously Presented)** The method of Claim 1, wherein said compound having an affinity for immunophilins is cyclosporin A.

**32. (Previously Presented)** The method of Claim 1, wherein said neurodegenerative illness is Parkinson's disease.

**33. (Previously Presented)** The method of Claim 1, wherein said neurodegenerative illness is Huntington's disease.

**34. (Previously Presented)** The method of Claim 1, wherein said neurodegenerative illness is stroke.

**35. (Previously Presented)** The method of Claim 1, wherein said neurodegenerative illness is amyotrophic lateral sclerosis.

**36. (Previously Presented)** The method of Claim 1, wherein said neurodegenerative illness is Alzheimer's disease.